top of page

ANCIENT WISDOM. MODERN SCIENCE.

Not Just Natural.
Clinically Proven.

Three independent studies. Two world-class institutions. Zero adverse events. Here is every result, in full.

CLINICAL EVIDENCE

3

independent studies

240

subjects tested

98.6%

non-irritant viability

0

adverse events

12M

stability confirmed

Repeated Insult
Patch Test

EUROFINS | CRL, INC. · PISCATAWAY, NJ

The gold standard for dermal safety. 240 male and female subjects aged 18–70, including 109 with self-perceived sensitive skin, underwent a full Repeated Insult Patch Test conducted to ICH GCP standards. Overseen by Winston Moy, MD — Diplomate of the American Board of Dermatology.

study 01

FIELD
DETAIL
Study Number
ECRLNJ2025-0577
Study Type
Repeated Insult Patch Test (RIPT)
Subjects
240 (male & female, ages 18–70)
Sensitive Skin
109 of 240 subjects
Fitzpatrick Types
I through VI — full range
Ethnicities
Caucasian, AA, Hispanic/Latino, Asian, Indian
Principal Investigator
Winston Moy, MD — American Board of Dermatology
Standard
ICH GCP
Adverse Events
✓ None reported
Protocol Deviations
✓ None
Study Period
June 13 – August 8, 2025

0

Adverse Events

ACROSS 240 SUBJECTS

· INCLUDING 109 SENSITIVE SKIN

"

The test material identified
as Hirudin Topical Serum
did not demonstrate a
potential for eliciting dermal
irritation or inducing
sensitization.

official study conclusion

EUROFINS | CRL, INC.

Skin Irritation Test
OECD 439

LIFENET HEALTH LIFESCIENCES · KALAMAZOO, MI

Conducted using the internationally validated MatTek EpiDerm™ reconstructed human epidermis model — the same system used by global cosmetic brands and accepted as a regulatory standard in the EU, US, and worldwide. Our product scored nearly double the required threshold for Non-Irritant classification.

study 02

FIELD
DETAIL
Study Period
June 2025
GHS Classification
✓ No Category — Non-Irritant to Skin
Our Result
98.6% — nearly double threshold
Non-Irritant Threshold
Mean viability >50%
Mean Tissue Viability
98.6% ± 4.5%
Test Concentration
2% Neat (commercial concentration)
Principal Investigator
Jamin A. Willoughby, Sr., Ph.D.
Test Model
MatTek EpiDerm™ reconstructed human epidermis
Standard
OECD Test Guideline 439
Study Number
LNH-S-095-003

98.6%

Tissue Viability

NON-IRRITANT THRESHOLD IS 50%

· PRODUCT SCORED 98.6%

12 Week Cosmetic
Stability Study

EUROFINS | CRL, INC. · PISCATAWAY, NJ

study 03

Rigorous accelerated stability study at 40°C / <60% RH — simulating extended real-world aging. Every key parameter evaluated at 3-week intervals including pH, viscosity, colour, texture, microbial count, and full preservative efficacy against five challenge organisms.

Parameter
Ambient
Stress
Status
Colour
No Change
No Change
✓ Pass
Odour / Fragrance
No Change
No Change
✓ Pass
Texture
No Change
No Change
✓ Pass
Weight
No Change
No Change
✓ Pass
Package Integrity
No Change
No Change
✓ Pass
pH
5.61 (Δ0.01)
5.45 (Δ0.17)
✓ Pass
Viscosity
73.0 (stable)
62.4 (acceptable)
✓ Pass
Preservative Efficacy
All 5 organisms eliminated within 7 days at every interval
All 5 organisms eliminated within 7 days at every interval
✓ Pass

Safe For Most.
Important Notes For Some.

SAFETY GUIDANCE

Anticoagulant Medications

Do not use if taking prescription anticoagulants (warfarin, heparin, apixaban) without consulting a healthcare professional first.

Pregnancy & Breastfeeding

Consult a healthcare professional before use if pregnant or breastfeeding.

Sensitive Skin

Clinically confirmed safe. 109 of 240 study subjects had self-perceived sensitive skin. Zero adverse events across the entire sensitive skin group.

All Skin Tones

Tested across Fitzpatrick types I–VI, representing Caucasian, African American, Hispanic/Latino, Asian, and Indian skin types.

External Use Only

Topical application only. Avoid eyes and mucous membranes. Keep out of reach of children.

Storage

Room temperature. Protect from direct sunlight. 12-week stability confirmed under 40°C / <60% RH.

This product is a cosmetic serum and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Statements represent the findings of independent third-party clinical testing. Results may vary.

Download All Three
Study Reports

Full PDFs of all three independent studies. Raw data, principal investigator signatures, and QA audit statements included.

contact our team
bottom of page